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Neuroguidin (NGDN) is a eukaryotic translation initiation factor 4E binding protein. The purpose of this study was to
clarify the function of NGDN and its possible mechanism of action in human myeloid leukemia cells. Proliferation
inhibition and apoptosis in NGDN over-expressing myeloid multidrug-resistant leukemia cells (K562/A02-NGDN) was
significantly higher than in control K562/A02 cells following treatment with vincristine, etoposide, and epirubicin,
indicating that NGDN over-expression can increase the sensitivity of multidrug-resistant leukemia cells to
chemotherapeutic drugs. Furthermore, NGDN knock-down in K562/A02 cells resulted in the activation of multiple
tumor-related signaling pathways, especially the mammalian target of rapamycin (mTOR) pathway.
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We previously reported the expression of some genes
with unknown functions in myeloid leukemia cell lines
and primary leukemia cells from clinical patients [1-3],
one of which was homologous to neuroguidin (NGDN)
[4]. Jung and colleagues confirmed that NGDN has a
similar structure and function to eukaryotic translation
initiation factor 4E (eIF4E) binding proteins [4], which
are known to inhibit the cap-dependent protein transla-
tion as negative regulators of eIF4E and are involved in
tumor cell proliferation, survival, and apoptosis [5-9].
Low expression and high phosphorylation of eIF4E bind-
ing protein 1 (4E-BP1) is associated with poor prognosis
and tumor invasion [10]. High expression of 4E-BPs
enhances tumor cell sensitivity to chemotherapeutic
drugs and is associated with favorable clinical prognosis
[11-13]. In this study, the effect of NGDN and its mech-
anism of action in human myeloid leukemia cells were
investigated.* Correspondence: shuqing7266@163.com; jmwang@medmail.com.cn
†Equal contributors
Department of Hematology, Changhai Hospital, Second Military Medical
University, 168 Changhai Road, Shanghai 200433, China
© 2015 Chen et al.; licensee BioMed Central. T
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.Effects of NGDN over-expression on proliferation and
apoptosis in multidrug-resistant leukemia cell line K562/A02
The human myeloid multidrug-resistant leukemia cell line
K562/A02 was used to generate NGDN over-expressing
leukemia cells (K562/A02-NGDN) by lentiviral transduc-
tion [see Additional files 1 and 2]. The proliferation of
K562/A02-NGDN cells and control K562/A02 cells were
assessed using the CCK-8 assay after treatment with
different concentrations of vincristine (VCR), etopo-
side (VP-16), and epirubicin (EPI) for different lengths
of time. Proliferation inhibition in K562/A02-NGDN
cells was significantly higher than in control K562/
A02 cells following treatment with each drug (P < 0.05)
(Figure 1A,B,C). For example, after a 50-μM EPI treat-
ment for 36 h, percent inhibition of K562/A02 and K562/
A02-NGDN cell proliferation was 45.73% ± 1.93% and
59.15% ± 2.75%, respectively (P < 0.05) (Figure 1C). These
results suggest that NGDN over-expression enhances the
inhibitory effect of chemotherapeutic drugs on multidrug-
resistant leukemia cell proliferation. Next, cell apoptosis
was assessed using flow cytometry following treatment
with different concentrations of VCR, VP-16, and EPI for
different lengths of time. Apoptosis in K562/A02-NGDN
cells was significantly higher than in K562/A02 cells
(P < 0.05) (Figure 1D,E,F). For example, after a 200-μM
EPI treatment for 24 h, the percentage of apoptosishis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Proliferation inhibition and apoptosis in NGDN over-expressing leukemia cells (K562/A02-NGDN) after chemotherapeutic
drugs treatment. The level of proliferation inhibition was examined using the CCK-8 assay following treatment with different concentrations of
chemotherapeutic drugs for different lengths of time. The percentages of proliferation inhibition in K562/A02-NGDN and control K562/A02 cells
after treatment with (A) vincristine (VCR), (B) etoposide (VP-16) and (C) epirubicin (EPI) are shown (mean ± SD, n = 3, star symbols: P < 0.05). The
level of apoptosis was assessed using annexin V-FITC/allophycocyanin (APC ) staining by flow cytometry. The percentages of apoptosis in K562/
A02-NGDN and control K562/A02 cells after treatment with (D) VCR, (E) VP-16, and (F) EPI are shown (mean ± SD, n = 3, star symbols: P < 0.05).
NGDN: neuroguidin.
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23.85% ± 1.06% and 41.9% ± 3.25%, respectively (P < 0.05)
(Figure 1F). These results suggest that NGDN over-
expression can also enhance the apoptosis-inducing effectof chemotherapeutic drugs on multidrug-resistant leuke-
mia cells. The effects of NGDN over-expression were also
confirmed in human myeloid leukemia line K562 [see
Additional files 1 and 3].
Table 1 The main genes up-regulated in NGDN knock-down
leukemia cells K562/A02-KD compared with negative control
cells K562/A02-NC (n = 3, P< 0.05)
Category Gene
name
Relative mRNA expression level
(K562/A02-KD/K562/A02-NC)



























IGF1 insulin-like growth factor 1, IGF1R receptor of insulin-like growth factor 1,
mTOR mammalian target of rapamycin, Akt protein kinase B, PDPK1 3-
phosphoinositide-dependent protein kinase-1, TSC1 tuberous sclerosis complex 1,
PKC protein kinase C, IL1R1 receptor 1 of interleukin 1, TOLLIP toll interacting
protein, MAPK3 mitogen-activated protein kinase 3, NF-κB2 Nuclear transcription
factor-kappa B 2, STAT2 signal transducer and activator of transcription 2, NFAT
nuclear factor of activated T cells, ELK1 ETS-like gene 1, E2F1 E2F transcription
factor 1, HSF1 heat shock factor 1, CTNN catenin, FN1 fibronectin 1, ITGAM integrin
alpha-M, VIM vimentin.
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To explore the mechanism of action of NGDN, a
NGDN knock-down cell line (K562/A02-KD) was gen-
erated from K562/A02 cells by lentiviral transduction
(transfected with small interfering RNA of NGDN),
and a negative control was also generated with unre-
lated RNA (K562/A02-NC) [see Additional files 1 and
4]. The mRNA levels of core proteins of multiple path-
ways were detected by quantitative real-time reverse
transcription PCR (qRT-PCR), including 4 housekeep-
ing genes and 92 mammalian target of rapamycin
(mTOR) pathway and mTOR-related pathway genes.
The mTOR pathway is an important target in cancer
therapy, as it is involved in the initiation of protein
translation necessary for cell growth through the
downstream effector 4E-BP1 and ribosomal protein S6
kinase [9,14]. qRT-PCR demonstrated a significant
difference in the expression levels of 69 genes between
K562/A02-KD and K562/A02-NC cells (P < 0.05). A
number of genes were up-regulated in K562/A02-KD
cells compared to K562/A02-NC cells (Table 1). For
example, extracellular signaling genes were up-
regulated including insulin-like growth factor 1(IGF1)
and receptor of IGF1. The signal transduction pathway
genes that were up-regulated in K562/A02-KD cells
are involved in the mTOR pathway, the toll-like recep-
tor signaling pathway, the mitogen-activated protein
kinase pathway, the nuclear transcription factor kappa
B pathway, and the Janus kinase/signal transducer and
activator of the transcription signaling pathway. The
up-regulated transcription factor genes include the
nuclear factor of activated T cells, and the up-
regulated cell invasion and metastasis-related genes in-
clude catenin and fibronectin 1. Oncogenes were also
up-regulated in K562/A02-KD cells including MYC,
Ras, and JUN. Some core genes of the mTOR pathway
were significantly up-regulated in K562/A02-KD cells,
including 3-phosphoinositide-dependent protein kinase-1,
Akt, and mTOR. These results demonstrate that
knock-down of the NGDN expression can activate
many tumor-related signaling pathways (especially the
mTOR pathway), which may promote tumor growth,
angiogenesis and cell invasion, and inhibit apoptosis.
The possible relationship between NGDN and the
mTOR pathway was expounded in Additional files 1
and 5.
Overall, the results of this study in vitro confirmed
that NGDN over-expression can increase the sensitiv-
ity of human myeloid multidrug-resistant leukemia
cells to chemotherapeutic drugs, indicating that the
high expression of NGDN may be a favorable prognos-
tic factor for patients with acute myeloid leukemia [see
Additional file 1]. The specific mechanism of action of
NGDN in leukemia cells requires further study.Additional files
Additional file 1: Supplementary data. The details of neuroguidin
(NGDN) over-expressing human myeloid leukemia cells and NGDN
knock-down leukemia cells generated by lentivirus transduction were
shown. The study in vitro confirmed that NGDN over-expression can
increase the sensitivity of human myeloid leukemia cells K562 to
chemotherapeutic drugs. The possible relationship between NGDN and
mammalian target of the rapamycin (mTOR) pathway was expounded.
We inferred that NGDN can be regulated by the mTOR pathway and also
regulate the mTOR pathway in a way of negative feedback. The results of
the study on acute myeloid leukemia (AML) patients suggest that high
NGDN mRNA expression level may be relative to the low bone marrow
blast cell proportion and less inducing chemotherapy courses to obtain
complete remission in AML patients.
Additional file 2: Figure S1. The NGDN over-expressing human
myeloid leukemia cells K562-NGDN and K562/A02-NGDN generated by
lentivirus transduction. K562-NGDN and K562/A02-NGDN: NGDN
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cell line K562 and its multidrug-resistant subline K562/A02. K562-CON:
Negative control K562 cells transfected with empty vector. The green
fluorescent protein (GFP) expressed in K562-NGDN, K562-CON, and K562/
A02-NGDN cells was observed by fluorescence microscope (A) and flow
cytometry (B). The mRNA expression levels of the NGDN gene detected
by real-time fluorescent quantitative reverse transcription-polymerase
chain reaction in K562-NGDN, K562-CON, and K562 cells were shown in
(C); the mRNA expression levels of NGDN in K562/A02-NGDN and K562/
A02 cells were shown in (D).
Additional file 3: Figure S2. Proliferation inhibition and apoptosis in
NGDN over-expressing leukemia cells (K562-NGDN) after chemotherapeutic
drug treatment. K562-CON: negative control cells transfected with an empty
vector. Proliferation inhibition was examined using the CCK-8 method after
treatment with different concentrations of chemotherapeutic drugs for
different lengths of time. The percentages of proliferation inhibition in
K562-NGDN and control cells after treatment with (A) vincristine (VCR), (B)
etoposide (VP-16), (C) daunorubicin (DNR), and (D) epirubicin (EPI) are
shown (mean ± SD, n = 3, star symbols: P < 0.05). The level of apoptosis was
assessed using annexin V-FITC/APC staining by flow cytometry. The
percentages of apoptosis in K562-NGDN and control cells after treatment
with (E) VCR, (F) VP-16, (G) (DNR), and (H) EPI are shown (mean ± SD, n = 3,
star symbols: P < 0.05).
Additional file 4: Figure S3. The NGDN knock-down cells K562/A02-KD
and negative control cells K562/A02-NC. The green fluorescent protein
(GFP) expressed in K562/A02-KD (A) and K562/A02-NC (B) cells was
observed by fluorescence microscope. (C) The mRNA expression levels of
NGDN in K562/A02-KD and K562/A02–NC cells were detected by
fluorescent quantitative reverse transcription-polymerase chain reaction.
Additional file 5: Figure S4. The possible relationship between NGDN
and mTOR pathway. eIF4E: eukaryotic translation initiation factor 4E;
4EBP1: eIF4E binding protein 1; mTOR: mammalian target of rapamycin;
IGF-1: insulin-like growth factors 1; IRS-1: insulin receptor substrate 1;
PDPK1: 3-phosphoinositide -dependent protein kinase-1; PI3K:
phosphatidylinositol 3-kinase; PKB/Akt: protein kinase B; RPS6K: ribosomal
protein S6 kinase. mTORC1 phosphorylated the P70S6K and 4EBP1 when
the insulin activated PI3K and mTOR in turn. Then, P70S6K promoted the
degradation of IRS-1 by way of negative feedback and eventually inhibited
the IRS-1-mediated activation of the mTOR pathway. NGDN may be
regulated by the mTOR pathway and also regulate the mTOR pathway in a
way of negative feedback similar to P70S6K/4EBP1. The red font represents
the possible NGND-regulated pathways.
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